Mutations in the tyrosine kinase domain of EGFR that are known to associate with response or resistance to EGFR therapy in other cancers are rare in patients with HNSCC and do not correlate with efficacy of EGFR-inhibition or clinical outcome [15]. Here, EGFR is linked to head and neck squamous cell carcinoma.